Status:
COMPLETED
Intralesional Versus Intramuscular Hepatitis B Vaccine Immunotherapy for Warts
Lead Sponsor:
Zagazig University
Conditions:
Intralesional Versus Intramuscular Hepatitis B Vaccine for Multiple Common Warts
Eligibility:
All Genders
10-60 years
Phase:
PHASE1
PHASE2
Brief Summary
Assessment of the effectiveness of intralesional and intramuscular hepatitis B vaccine in treatment of multiple common warts.
Detailed Description
Recently, intralesional immunotherapy by different antigens, including Candida antigen and purified protein derivative PPD has been proved effective in the treatment of different types of warts. Hepat...
Eligibility Criteria
Inclusion
- • Adult patients of both sexes with multiple (\> 3 warts) common warts of various sites, sizes and duration, with or without distant warts after taking informed consent from all patients
Exclusion
- Pregnancy or lactation.
- Serious systemic or anaphylactic reaction to a prior dose of the vaccine or to any of its components.
- Allergic skin disorders such as generalized eczema and urticaria.
- Moderate or severe acute illness with or without fever.
- Previous wart therapy within 1 month prior to the study.
Key Trial Info
Start Date :
November 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 25 2021
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05326152
Start Date
November 25 2020
End Date
October 25 2021
Last Update
April 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig university
Zagazig, Sharqia Province, Egypt, 44519